Ardent Health financials
$10.58+1.05%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.62B | $1.60B | $1.61B | $1.58B | $1.65B | $1.50B | $1.61B | $1.45B |
| Gross profit | $1.62B | $1.60B | $1.61B | $1.58B | $1.65B | $1.50B | $1.61B | $1.45B |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating income | $55.8M | $86.8M | $104.8M | $16.5M | $136.7M | $88.4M | $157.6M | $70.4M |
| Net income | $16.9M | $39.9M | $45.0M | -$23.5M | $73.0M | $41.4M | $114.2M | $26.3M |
| Net margin | 1.0% | 2.5% | 2.8% | −1.5% | 4.4% | 2.8% | 7.1% | 1.8% |
| Diluted EPS | $0.12 | $0.28 | $0.32 | $-0.17 | $0.52 | $0.29 | $0.81 | $0.19 |
| EBITDA | $97.1M | $129.8M | $145.8M | $55.6M | $176.0M | $124.6M | $195.4M | $107.2M |
| Operating cash flow | $196.7M | -$60.2M | $223.4M | $154.4M | $117.5M | -$24.8M | $119.6M | $89.7M |
| Free cash flow | $168.6M | -$88.3M | $139.4M | $95.6M | $94.6M | -$47.7M | $38.3M | $46.2M |
| Diluted shares | 143.1M | 141.8M | 142.4M | 141.2M | 141.5M | 140.7M | 141.2M | 137.5M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $724.5M | $609.7M | $709.6M | $609.4M | $540.6M | $495.0M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $1.10B | $1.11B | $1.10B | $1.11B | $1.11B | $1.11B |
| Total assets | $5.28B | $5.25B | $5.29B | $5.15B | $5.03B | $4.91B |
| Total liabilities | $3.54B | $3.52B | $3.61B | $3.52B | $3.38B | $3.35B |
| Shareholders' equity | $1.75B | $1.73B | $1.69B | $1.63B | $1.65B | $1.56B |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology